Randomiserede, enkeltblinde, crossover- forsøg med enkeltdosis, der omfattede 196 raske forsøgspersoner, viste, at Filgrastim ratiopharms farmakokinetiske profil var sammenlignelig med profilen af referenceproduktet efter subkutan og intravenøs administration.
Randomised, single-blind, single dose, crossover studies in 196 healthy volunteers showed that the pharmacokinetic profile of Filgrastim ratiopharm was comparable to that of the reference product after subcutaneous and intravenous administration.